In a meta-analysis of 4,752 patients with advanced-stage NSCLC treated with various ALK TKIs, subgroup analysis of the brigatinib-treated patients demonstrated a 7% incidence of all-grade pneumonitis and a 3% incidence of high-grade pneumonitis (10). Here, ALK is linked to non-small cell lung carcinoma.